Insider Selling: Artivion (NYSE:AORT) CEO Sells 30,921 Shares of Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 30,921 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $45.56, for a total transaction of $1,408,760.76. Following the sale, the chief executive officer owned 800,993 shares in the company, valued at $36,493,241.08. This represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Artivion Trading Up 0.5%

AORT stock traded up $0.22 during mid-day trading on Wednesday, reaching $45.59. 493,494 shares of the stock traded hands, compared to its average volume of 430,927. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.04. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.88 and a current ratio of 3.93. The business has a 50-day moving average price of $43.86 and a two-hundred day moving average price of $37.95. The stock has a market capitalization of $2.16 billion, a PE ratio of -189.95 and a beta of 1.60.

Artivion (NYSE:AORT) last released its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. The firm had revenue of $113.39 million for the quarter, compared to analysts’ expectations of $110.71 million. Artivion had a positive return on equity of 5.98% and a negative net margin of 2.16%.The business’s quarterly revenue was up 18.9% on a year-over-year basis. Equities research analysts expect that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Trading of Artivion

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Artivion by 8.3% during the third quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock worth $128,250,000 after purchasing an additional 232,424 shares in the last quarter. Wellington Management Group LLP raised its position in Artivion by 4.1% in the 1st quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company’s stock valued at $42,460,000 after purchasing an additional 67,327 shares during the last quarter. Next Century Growth Investors LLC grew its position in Artivion by 107.6% during the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock worth $25,140,000 after purchasing an additional 530,122 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Artivion by 22.8% in the second quarter. Bank of America Corp DE now owns 645,070 shares of the company’s stock valued at $20,062,000 after buying an additional 119,634 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Artivion by 40.8% during the second quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after buying an additional 139,370 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Analyst Ratings Changes

AORT has been the topic of a number of recent research reports. Needham & Company LLC raised their price objective on Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Citigroup reiterated an “outperform” rating on shares of Artivion in a research report on Friday, October 10th. Stifel Nicolaus upped their price target on Artivion from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Citizens Jmp boosted their price objective on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Finally, Canaccord Genuity Group raised their price objective on shares of Artivion from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.